Cost-effectiveness acceptability curves revisited
Since the introduction of the cost-effectiveness acceptability curve (CEAC) in 1994, its use as a method to describe uncertainty around incremental cost-effectiveness ratios (ICERs) has steadily increased. In this paper, first the construction and interpretation of the CEAC is explained, both in the context of modelling studies and in the context of cost-effectiveness (CE) studies alongside clinical trials. Additionally, this paper reviews the advantages and limitations of the CEAC. Many of the perceived limitations can be attributed to the practice of interpreting the CEAC as a decision rule while it was not developed as such. It is argued that the CEAC is still a useful tool in describing and quantifying uncertainty around the ICER, especially in combination with other tools such as plots on the CE plane and value-of-information analysis.
|Keywords||cost-effectiveness, healthcare, pharmacoeconomics|
|Persistent URL||dx.doi.org/10.1007/s40273-012-0011-8, hdl.handle.net/1765/50733|
Al, M.J. (2013). Cost-effectiveness acceptability curves revisited. PharmacoEconomics, 31(2), 93–100. doi:10.1007/s40273-012-0011-8